Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Children | European Medicines Agency (EMA) | Hepatitis | Hepatitis C | Pegasys | Pharmaceuticals